Biogen Idec Inc. (BIIB)
-NasdaqGS 226.85 
1.14(0.50%) May 17, 4:00PM EDT|After Hours
:
226.50 0.35 (0.15%) May 17, 6:12PM EDT
| Prev Close: | 227.99 |
|---|
| Open: | 227.95 |
|---|
| Bid: | 206.10 x 100 |
|---|
| Ask: | 228.79 x 100 |
|---|
| 1y Target Est: | 220.11 |
|---|
| Beta: | 1.29 |
|---|
| Next Earnings Date: | 22-Jul-13 |
|---|
| Day's Range: | 224.60 - 228.86 |
|---|
| 52wk Range: | 126.39 - 231.99 |
|---|
| Volume: | 1,243,879 |
|---|
| Avg Vol (3m): | 1,371,540 |
|---|
| Market Cap: | 53.85B |
|---|
| P/E (ttm): | 36.00 |
|---|
| EPS (ttm): | 6.30 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- IBD 50: Top 5 Medical Stocks Include Celgene, Actavisat Investor's Business Daily(Sat 8:05AM EDT)
- InPlay: Biogen Idec and Genentech have filed for a re-hearing of U.S. Court of Appeals decision in the Arzerra patent infringement caseBriefing.com(Fri, May 17)
- Data show new Roche leukemia drug may improve on Rituxanat Reuters(Thu, May 16)
- Investing in Health Care Innovation: A Wall Street Transcript Interview with Finny Kuruvilla, Portfolio Manager of the Eventide Gilead FundWall Street Transcript(Thu, May 16)
- AGN, LLY, BIIB, CELG And AMGN, Pushing Health Care Sector Downwardat TheStreet(Thu, May 16)
- 2 Scariest Dividend Stocks in Health Careat Motley Fool(Thu, May 16)
- Roche Experimental Leukemia Drug Helps Shrink Tumorsat Bloomberg(Thu, May 16)
- Data shows new Roche leukemia drug may improve on Rituxanat Reuters(Wed, May 15)
- Biogen Idec Inc (BIIB): Today's Featured Health Care Laggardat TheStreet(Wed, May 15)
- Jim Cramer: Buy AOL, Celgene, Biogen, and This Hot Stock Nowat Wall St. Cheat Sheet(Wed, May 15)
- [video] Cramer's '4 Horsemen of the Apocalypse' for Shortsat CNBC(Wed, May 15)
- Jim Cramer's 5 Investing Sweet Spotsat CNBC(Tue, May 14)
- MainStay Large Cap Growth Nibbles On Appleat Investor's Business Daily(Tue, May 14)
- Isis Gets $3.5M Milestone PaymentZacks(Tue, May 14)
- Biogen Idec Stock Hits New 52-Week High (BIIB)at TheStreet(Tue, May 14)
Key Statistics
| Forward P/E (1 yr): | 22.89 |
|---|
| P/S (ttm): | 9.60 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 8.04 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 1.90 |
|---|
| Mean Recommendation*: | 2.1 |
|---|
| PEG Ratio (5 yr expected): | 1.53 |
|---|
Business Summary
Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally.
View More